13 results on '"Cui, Guang-Lin"'
Search Results
2. Widespread myocardial dysfunction in COVID-19 patients detected by myocardial strain imaging using 2-D speckle-tracking echocardiography
- Author
-
Li, Rui, Wang, Hong, Ma, Fei, Cui, Guang-lin, Peng, Li-yuan, Li, Chen-ze, Zeng, He-song, Marian, Ali J., and Wang, Dao-wen
- Published
- 2021
- Full Text
- View/download PDF
3. Dynamic changes in liver function parameters in patients with coronavirus disease 2019: a multicentre, retrospective study
- Author
-
Zeng, Qing-Lei, Yu, Zu-Jiang, Ji, Fanpu, Li, Guang-Ming, Zhang, Guo-Fan, Xu, Jiang-Hai, Lin, Wan-Bao, Zhang, Guo-Qiang, Li, Guo-Tao, Cui, Guang-Lin, and Wang, Fu-Sheng
- Published
- 2021
- Full Text
- View/download PDF
4. Sofosbuvir‐based therapy for late pregnant women and infants with severe chronic hepatitis C: A case series study.
- Author
-
Zeng, Qing‐Lei, Yu, Zu‐Jiang, Lv, Jun, Zhang, Hong‐Xu, Wang, Bin, Dong, Xiao‐Ping, Chen, Zhi‐Min, Cui, Guang‐Lin, and Ji, Fanpu
- Subjects
CHRONIC hepatitis C ,PREGNANT women ,NEWBORN infants ,HEPATITIS C ,HEPATITIS C virus ,INFANTS - Abstract
Data on sofosbuvir‐based therapy for pregnant women and infants with severe chronic hepatitis C (CHC) are lacking. Two late pregnant women and one female infant with severe CHC were enrolled for treatment. Pregnant Women 1 and 2 and Infant 3 were 30, 33, and 1.2 years old, respectively; the gestational ages of pregnant Women 1 and 2 were 31 and 26 weeks, respectively. Notably, pregnant Women 1 and 2 and Infant 3 had hepatitis C virus (HCV) RNA levels of 139 000, 198 000, and 8 450 000 IU/ml; alanine aminotransferase levels of 420, 781, and 220 U/L; and received sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and sofosbuvir/ledipasvir for 12 weeks, respectively. All three patients were safely cured with favorable tolerance, and two newborns were both breastfeeding and were consistently negative for the anti‐HCV antibody during the 1‐year follow‐up after birth. Additionally, two newborns and Infant 3 had normal growth parameters during the follow‐up year one. In conclusion, this case series study found that sofosbuvir‐based therapy for pregnant women and infants with severe CHC is safe and effective. The data may fill the gap and provide evidence of the use of sofosbuvir‐based therapy as a reference when similar severe CHC situations are encountered during clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients
- Author
-
Zeng, Qing-Lei, Yu, Zu-Jiang, Gou, Jian-Jun, Li, Guang-Ming, Ma, Shu-Huan, Zhang, Guo-Fan, Xu, Jiang-Hai, Lin, Wan-Bao, Cui, Guang-Lin, Zhang, Min-Min, Li, Cheng, Wang, Ze-Shuai, Zhang, Zhi-Hao, and Liu, Zhang-Suo
- Subjects
Coronavirus disease 2019 (COVID-19) ,Survival rate ,AcademicSubjects/MED00290 ,viruses ,Brief Report ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Viral shedding ,Fatality ,AcademicSubjects/MED00860 ,Convalescent plasma therapy - Abstract
Currently, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) has been reported in almost all countries globally, and no effective therapy has been documented for COVID-19 and the role of convalescent plasma therapy is unknown. In current study, 6 COVID-19 subjects with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding, all tested negative for SARS-CoV-2 RNA by 3 days after infusion, and 5 died eventually. In conclusion, convalescent plasma treatment can discontinue SARS-CoV-2 shedding but cannot reduce mortality in critically end-stage COVID-19 patients, and treatment should be initiated earlier.
- Published
- 2020
6. Tenofovir Alafenamide to Prevent Perinatal Hepatitis B Transmission: A Multicenter, Prospective, Observational Study.
- Author
-
Zeng, Qing-Lei, Yu, Zu-Jiang, Ji, Fanpu, Li, Guang-Ming, Zhang, Guo-Fan, Xu, Jiang-Hai, Chen, Zhi-Min, Cui, Guang-Lin, Li, Wei, Zhang, Da-Wei, Li, Juan, Lv, Jun, Li, Zhi-Qin, Liang, Hong-Xia, Sun, Chang-Yu, Pan, Ya-Jie, Liu, Yan-Min, and Wang, Fu-Sheng
- Subjects
HEPATITIS B prevention ,RESEARCH ,SCIENTIFIC observation ,TENOFOVIR ,ANTIVIRAL agents ,MEDICAL cooperation ,PREGNANT women ,FETAL development ,NEURAL development ,RESEARCH funding ,PUERPERIUM ,PREVENTIVE medicine ,VERTICAL transmission (Communicable diseases) ,LONGITUDINAL method ,ALANINE aminotransferase ,PREGNANCY - Abstract
Background Few safety and effectiveness results have been published regarding the administration of tenofovir alafenamide fumarate (TAF) during pregnancy for the prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV). Methods In this multicenter prospective observational study, pregnant women with HBV DNA levels higher than 200 000 IU/mL who received TAF or tenofovir disoproxil fumarate (TDF) from gestational weeks 24–35 to delivery were 1:1 enrolled and followed until postpartum month 6. Infants received immunoprophylaxis. The primary endpoint was the safety of mothers and infants. The secondary endpoint was the hepatitis B surface antigen (HBsAg)-positive rate at 7 months for infants. Results In total, 116 and 116 mothers were enrolled, and 117 and 116 infants were born, in the TAF and TDF groups, respectively. TAF was well tolerated during a mean treatment duration of 11.0 weeks. The most common maternal adverse event was nausea (19.0%). One (0.9%), 3 (2.6%), and 9 (7.8%) mothers had abnormal alanine aminotransferase levels at delivery and at postpartum months 3 and 6, respectively. The TDF group had safety profiles that were comparable to those of the TAF group. No infants had birth defects in either group. The infants' physical and neurological development at birth and at 7 months in the TAF group were comparable with those in the TDF group. The HBsAg positive rate was 0% at 7 months in all 233 infants. Conclusions Antiviral prophylaxis with TAF was determined to be generally safe for both mothers and infants and reduced the MTCT rate to 0%. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Genomic Epidemiology of SARS-CoV-2 From Mainland China With Newly Obtained Genomes From Henan Province.
- Author
-
Song, Ning, Cui, Guang-Lin, and Zeng, Qing-Lei
- Subjects
SARS-CoV-2 ,NUCLEOTIDE sequencing ,MOLECULAR epidemiology ,GENETIC variation ,METAGENOMICS ,COVID-19 treatment - Abstract
Even though the COVID-19 epidemic in China has been successfully put under control within a few months, it is still very important to infer the origin time and genetic diversity from the perspective of the whole genome sequence of its agent, SARS-CoV-2. Yet, the sequence of the entire virus genome from China in the current public database is very unevenly distributed with reference to time and place of collection. In particular, only one sequence was obtained in Henan province, adjacent to China's worst-case province, Hubei Province. Herein, we used high-throughput sequencing techniques to get 19 whole-genome sequences of SARS-CoV-2 from 18 severe patients admitted to the First Affiliated Hospital of Zhengzhou University, a provincial designated hospital for the treatment of severe COVID-19 cases in Henan province. The demographic, baseline, and clinical characteristics of these patients were described. To investigate the molecular epidemiology of SARS-CoV-2 of the current COVID-19 outbreak in China, 729 genome sequences (including 19 sequences from this study) sampled from Mainland China were analyzed with state-of-the-art comprehensive methods, including likelihood-mapping, split network, ML phylogenetic, and Bayesian time-scaled phylogenetic analyses. We estimated that the evolutionary rate and the time to the most recent common ancestor (TMRCA) of SARS-CoV-2 from Mainland China were 9.25 × 10
−4 substitutions per site per year (95% BCI: 6.75 × 10−4 to 1.28 × 10−3 ) and October 1, 2019 (95% BCI: August 22, 2019 to November 6, 2019), respectively. Our results contribute to studying the molecular epidemiology and genetic diversity of SARS-CoV-2 over time in Mainland China. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. Clinical course and treatment efficacy of COVID‐19 near Hubei Province, China: A multicentre, retrospective study.
- Author
-
Zeng, Qing‐Lei, Li, Guang‐Ming, Ji, Fanpu, Ma, Shu‐Huan, Zhang, Guo‐Fan, Xu, Jiang‐Hai, Lin, Wan‐Bao, Xu, Guang‐Hua, Zhang, Guo‐Qiang, Li, Guo‐Tao, Cui, Guang‐Lin, Liu, Na, Zeng, Fan‐Jun, Ai, Zhi‐Guo, Xu, Guang‐Feng, Liang, Jie, Zhang, Min‐Min, Li, Cheng, Zhang, Zhi‐Hao, and Wang, Ze‐Shuai
- Subjects
COVID-19 treatment ,COVID-19 ,VIRAL shedding ,ANTIVIRAL agents - Abstract
Currently, COVID‐19 has been reported in nearly all countries globally. To date, little is known about the viral shedding duration, clinical course and treatment efficacy of COVID‐19 near Hubei Province, China. This multicentre, retrospective study was performed in 12 hospitals in Henan and Shaanxi Provinces from 20 January to 8 February 2020. Clinical outcomes were followed up until 26 March 2020. The viral shedding duration, full clinical course and treatment efficacy were analysed in different subgroups of patients. A total of 149 COVID‐19 patients were enrolled. The median age was 42 years, and 61.1% (91) were males. Of them, 133 (89.3%) had fever, 131 of 144 (91%) had pneumonia, 27 (18.1%) required intensive care unit (ICU) management, 3 (2%) were pregnant, and 3 (2%) died. Two premature newborns were negative for SARS‐CoV‐2. In total, the median SARS‐CoV‐2 shedding period and clinical course were 12 (IQR: 9–17; mean: 13.4, 95% CI: 12.5, 14.2) and 20 (IQR: 16–24; mean: 21.2, 95% CI: 20.1, 22.3) days, respectively, and ICU patients had longer median viral shedding periods (21 [17–24] versus 11 [9–15]) and clinical courses (30 [22–33] vs. 19 [15.8–22]) than non‐ICU patients (both p <.0001). SARS‐CoV‐2 clearances occurred at least 2 days before fatality in 3 non‐survivors. Current treatment with any anti‐viral agent or combination did not present the benefit of shortening viral shedding period and clinical course (all p >.05) in real‐life settings. In conclusion, the viral shedding duration and clinical course in Henan and Shaanxi Provinces were shorter than those in Hubei Province, and current anti‐viral therapies were ineffective for shortening viral shedding duration and clinical course in real‐world settings. These findings expand our knowledge of the SARS‐CoV‐2 infection and may be helpful for management of the epidemic outbreak of COVID‐19 worldwide. Further studies concerning effective anti‐viral agents and vaccines are urgently needed. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019.
- Author
-
Zeng, Qing-Lei, Yu, Zu-Jiang, Gou, Jian-Jun, Li, Guang-Ming, Ma, Shu-Huan, Zhang, Guo-Fan, Xu, Jiang-Hai, Lin, Wan-Bao, Cui, Guang-Lin, Zhang, Min-Min, Li, Cheng, Wang, Ze-Shuai, Zhang, Zhi-Hao, and Liu, Zhang-Suo
- Subjects
COVID-19 ,VIRAL shedding ,CONVALESCENT plasma - Abstract
Currently, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been reported in almost all countries globally. No effective therapy has been documented for COVID-19, and the role of convalescent plasma therapy is unknown. In the current study, 6 patients with COVID-19 and respiratory failure received convalescent plasma a median of 21.5 days after viral shedding was first detected, all tested negative for SARS-CoV-2 RNA within 3 days after infusion, and 5 eventually died. In conclusion, convalescent plasma treatment can end SARS-CoV-2 shedding but cannot reduce the mortality rate in critically ill patients with end-stage COVID-19, and treatment should be initiated earlier. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. miR‐1322 regulates ChREBP expression via binding a 3′‐UTR variant (rs1051943).
- Author
-
Zhang, Ying, Hu, Sen‐Lin, Hu, Dong, Jiang, Jian‐Gang, Cui, Guang‐Lin, Liu, Xing‐De, and Wang, Dao Wen
- Subjects
MICRORNA ,CARBOHYDRATES ,CARRIER proteins ,LIPID metabolism ,GLUCOSE metabolism - Abstract
The carbohydrate response element‐binding protein (ChREBP), also referred to as MLXIPL, plays a crucial role in the regulation of glucose and lipid metabolism. Existing studies have shown an association between genetic variations of the ChREBP gene and lipid levels, such as triglycerides and high‐density lipoprotein cholesterol. However, mechanistic studies of this association are limited. In this study, bioinformatic analysis revealed that the polymorphism rs1051943A occurs in the complementary binding sequence of miR‐1322 in the ChREBP 3′‐untranslated region (UTR). Studies of potential mechanisms showed that the A allele could facilitate miR‐1322 binding, and luciferase activity significantly decreased when co‐transfected with a ChREBP 3′‐UTR luciferase reporter vector and miR‐1322 mimics in HepG2 cells. Furthermore, miR‐1322 significantly regulated the expression of ChREBP downstream genes and reduced the synthesis of lipids. The expression of miR‐1322 was up‐regulated by glucose and palmitic acid stimulation. Population studies showed that rs1051943‐A allele was only found in the Han Chinese and Uighur ethnic groups, different from European populations (G allele frequency = 0.07). In summary, we provide evidence that the rs1051943 A allele creates a functional miR‐1322 binding site in ChREBP 3′‐UTR and post‐transcriptionally down‐regulates its expression, possibly associated with levels of plasma lipids and glucose. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Functional Aspects of the ECL Cell in Rodents
- Author
-
Cui, Guang-Lin and Norges teknisk-naturvitenskapelige universitet, Det medisinske fakultet
- Subjects
endocrine system ,digestive, oral, and skin physiology - Abstract
Gastric acid plays an important role in digesting food (especially proteins), iron absorption, and destroying swallowed micro-organism. N4 is secreted by the oxyntic parietal cells. Its secretion is regulated by endocrine, neurocrine and paracrine mechanisms. Gastrin released from the antral G cell is the principal physiological stimulus of gastric acid secretion. The ECL cell is accepted as the source of histamine participating in the regulation o f acid secretion and is functionally and trophically controlled by gastrin. Amidated gastrin is the main biologically active form of gastrin, and its main precursor Gly-G-17 was formerly thought to be without any biological activity. However, recent studies raised the possibility of both secretory and trophic effects of Gly-gastrin. No Glt-G-17 receptor has been cloned yet. In paper I, the effect of this peptide on gastric acid secretion was examined in the totally isolated vascularly perfused rat stomach. This study clearly demonstrates that the administration of Gly-G-17 in high doses was followed by an increase in histamine release and gastric acid output. Moreover, Gly-G-17 induced gastric acid secretion was completely inhibited by the H2 receptor antagonist ranitidine. Thus, the natural interpretation of these data is that Gly-G-17 is a weak gastrin agonist, interacting with the CCK-2 receptor on the ECL cell, resulting in a subsequent release of histamine, which in turn stimulates the parietal cell. The stomach is also regulated by nerves, principally by the vagal nerves. The gastric neurons contain various neuropeptides, some of them, such ad PACAP are known to influence gastric acid secretion. In paper II, PACAP was studied with respect to the effect on gastric acid secretion using totally isolated vascularly perfused rat stomachs, chronic fistula rats and isolated parietal cells. The results show that its stimulatory effects on gastric acid secretion is mainly due to an increase in histamine release from the ECL cell. PACAP is a powerful stimulator of histamine release from the ECL cell. As mentioned above, aside from its stimulatory effect on gastric acid secretion, gastrin also has a trophic effect on the oxyntic mucosa, especially on the ECL cell. A definite connection has been found between hypergastrinemia and gastric carcinoids both in rats and humans. Moreover, some of the gastric adenocarcinomas in rodents with hypergastrinemia have been reclassified as ECLomas. However, spontaneous gastric ECL omas in laboratory animals are extremely rare. Japanese cotton rats (Sigmodon hispidus) have a very high incidence of gastric carcinomas occurring predominately in females, and which we previously showed, were associated with achlorhydria and hypergastrinemia. In paper III, the gastric carcinomas in cotton rats are described further. Particularly the oxyntic mucosa outside the tumour is shown to contain normal parietal cells indicating a normal ability to produce acid. Long-term potent inhibitors of acid secretion resulting in secondary hypergastrinemia will induce ECL cell hyperplasia and probably carcinoids. Accordingly, the induction of ECL-cell hyperplasia and carcinoids remains a topic of considerable concern, especially in young individuals. Furthermore, the stomach is important for the absorption of calcium. Achlorhydria has been described as causing impairment of calcium absorption. Thus, a mechanism related to gastric acid secretion has been postulated to be involved in osteopenia developing in patients after gastric resection. More specifically, a postulated peptide, gastrocalcin, has been hypothesised to exist in the ECL cell. We therefore examined the effect of long-term hypergastrinemia secondary to drug induced hypoacidity with respect to bone developing in young male rats (paper IV). Long-term potent acid inhibition evoked a marked increase in plasma gastrin levels, leading to enlargement of oxyntic mucosa with ECL cell hyperplasia. However, body weight and bone mineral density were reduced in the hypergastrinemic young male rats. These findings do not support the hypothesis that the ECL cell plays a role in bone metabolism. Finally, anaesthetized animal models have been widely used to study gastric acid secretion. However, anaesthetic agents also affect acid output. Anaesthetic agents naturally reduce acid secretion by interaction with neural activity, but could also play a role by affecting the function of the different cells taking part in the regulatory chain of acid secretion as well as the parietal cell itself. In paper V, the totally isolated vascularly perfused rat stomach was used to study the effect of anaesthetic agents on the ECL cell and the parietal cell functions. The results indicate that anaesthetic agents can also affect gastric acid secretion through a direct inhibitory action on parietal cells and ECL cells. dr.med. dr.med.
- Published
- 2001
12. Immunohistochemical study on endocrine-like tumor cells in colorectal carcinomas
- Author
-
Wang, Dao-Cun, Wang, Li-Dong, Jia, Yun-Ying, Liu, Yi-Qing, Feng, Chang-Wei, Tang, Fu-Ai, Qi-Zhou, Li, Zhen-Feng, and Cui, Guang-Lin
- Subjects
Brief Reports - Abstract
To evaluate the clinical significance of endocrine-like tumor cells in human colorectal carcinomas.The immunohistochemistry method (ABC) using a rabbit polyclonal antibody against human chromogranin A (CGA) was employed to determine changes in endocrine-like tumor cells from the surgically resected colorectal carcinoma tissues of patients (35 males and 27 females, aged from 19 to 78 years, with a mean age of 50.3 years). Of the 62 specimens, 44 were from rectal carcinomas, 18 from colonic carcinomas, 14 from lymph nodes and 48 from non-involvement. Dukes classification revealed 19 of the cases were in stage A, 29 cases were in stage B and 14 cases were in stage C. All of the specimens were fixed with 10% formalin, embedded with paraffin and cut into 5 μm sections. Additionally, the correlations among CGA-positive tumor cells, as well as the clinicopathologic data, age and sex of the patients, were also investigated.CGA-positive tumor cells were found in 35.5% of the patients with colorectal cancers, representing 20.0% (5 of 25) and 45.9% (17 of 37) of the aged and non-aged, respectively. These differences were significant (χ(2) test, P0.05). Nevertheless, no significant correlations were found between the CGA-positive tumor cells and the sex, Dukes stages, tumor location, degree of histological differentiation or presence of lymph node metastasis.The low incidence of endocrine-like tumor cells found in the aged patients may be a new pathological feature for colorectal carcinomas, which could explain why the aged patients usually had a better prognosis. The exact significance of these findings requires further characterization.
- Published
- 1997
13. An APOC3 3′UTR variant associated with plasma triglycerides levels and coronary heart disease by creating a functional miR-4271 binding site.
- Author
-
Hu, Sen-Lin, Cui, Guang-Lin, Huang, Jin, Jiang, Jian-Gang, and Wang, Dao-Wen
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.